Onyx and Eli Lilly Expand Their Research Alliance on BRCA1

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

RICHMOND, Ca--Onyx Pharmaceuticals has announced an extension and expansion of its research alliance with Eli Lilly focusing on BRCA1, the gene linked to increased risk of breast and ovarian cancer. Lilly has exclusive rights to the BRCA1 gene by license from Myriad Genetics, Inc.

RICHMOND, Ca--Onyx Pharmaceuticals has announced an extensionand expansion of its research alliance with Eli Lilly focusingon BRCA1, the gene linked to increased risk of breast and ovariancancer. Lilly has exclusive rights to the BRCA1 gene by licensefrom Myriad Genetics, Inc.

The collaboration, originally begun in May 1995, aims to understandthe role of BRCA1-related pathways in breast cancer and to identifyproteins that interact with the gene that could be used to developtherapeutics.

Articles in this issue
Chemo Improves Pain Relief in Advanced Prostate Cancer
Multimedia Computer Program Patiently Answers Young Cancer Patients' Questions
NCCR Urges Congress to Support Senate Bill for Cancer Research
Researchers Propose New Treatment Guidelines for HIV
Salvage Cryotherapy for Prostate Cancer Studied at M.D. Anderson
FNA Dropped From RDOG Study Due To High Rate of Insufficient Samples
New Thinking on HIV Progression Leads to New Strategies
Hospitals Told Not to Capitate for 'Wrong' Reasons
More Study Needed of Possible Carcinogenesis of Winter Gas Additive
President Makes NCAB Appointments
Algorithm Identifies Women at Risk of Ovarian Cancer
Three Million a Year Die From Tobacco-Related Causes
Marketing of Cancer Services Must Include All Payer Modalities
Dr. Kessler Corrects Misapprehension That The FDA Cannot Regulate Tobacco Products
New Surgical Techniques May Reduce Impotence, Incontinence
Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content
Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care

Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care

Roman Fabbricatore
September 27th 2025
Article

Artificial intelligence can be used to automate genetic counseling processes and streamline a patient’s communication with relatives regarding genetic risk.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

The FDA has assigned a Prescription Drug User Fee Act date of July 11, 2026, for relacorilant as a treatment for platinum-resistant ovarian cancer.

FDA Accepts Relacorilant NDA for Platinum-Resistant Ovarian Cancer

Roman Fabbricatore
September 10th 2025
Article

The FDA has assigned a Prescription Drug User Fee Act date of July 11, 2026, for relacorilant as a treatment for platinum-resistant ovarian cancer.

Target Folate Receptor Alpha in Ovarian Cancer?

Target Folate Receptor Alpha in Ovarian Cancer?

Dmitriy Zamarin, MD, PhD
September 17th 2018
Podcast

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Ariana Pelosci
August 27th 2025
Article

The novel treatment was evaluated in a phase 2 trial and saw a clinical benefit in patients with advanced ovarian cancer.

Additional research on novel targeted therapies may be necessary to address the unmet needs in this high-grade serous ovarian cancer population.

Alpelisib Combo Does Not Extend PFS in High-Grade Serous Ovarian Cancer

Russ Conroy
August 13th 2025
Article

Additional research on novel targeted therapies may be necessary to address the unmet needs in this high-grade serous ovarian cancer population.